Post-hoc analysis shows efficacy of Spiriva Respimat (tiotropium bromide) in asthma- Boehringer

Boehringer announced the presentation of new post-hoc analyses that show the addition of Spiriva Respimat (tiotropium bromide) to other asthma maintenance therapies helps improve lung function and asthma symptom control, while reducing asthma exacerbations (also known as flare-ups), independent of a patient's subtype of allergic asthma. These analyses evaluated the safety and efficacy of adding Spiriva Respimat to other maintenance therapies compared to placebo across the broad range of asthma patients studied, regardless of immunoglobulin E (IgE) or eosinophil levels.

The addition of Spiriva Respimat significantly improved lung function. Adding Spiriva Respimat also was shown to improve asthma symptom control, as measured by the seven question Asthma Control Questionnaire (ACQ-7) and reduce the risk of asthma worsening and exacerbations. The ACQ-7 results in the pooled analysis did not distinguish among the treatment arms. These data were presented at the 2016 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Los Angeles.